GlassScriptPhysician profile
Aaron Chidakel
NPI 1245341619
$4,809.44
in general payments reported to CMS, 2019-2025
21 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,529 · 2020: $489 · 2021: $58.69 · 2022: $1,702 · 2023: $478 · 2024: $409 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $934.25 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $578.55 | 2020-2023 | Trulance |
| Lilly USA, LLC | $545.19 | 2019-2024 | Zepbound |
| Cequr Corporation | $449.88 | 2022-2023 | Cequr Simplicity |
| Abbvie INC. | $373.98 | 2020-2022 | |
| Amgen INC. | $311.36 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $257.25 | 2019-2022 | |
| Antares Pharma, INC. | $215.04 | 2019-2022 | |
| Medtronic Minimed, INC. | $150.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.53 | 2022 | |
| Mannkind Corporation | $125.01 | 2019 | |
| Ucb, INC. | $125.00 | 2022 | |
| Radius Health, INC. | $120.53 | 2019 | |
| Insulet Corporation | $120.45 | 2020 | |
| Genzyme Corporation | $118.57 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $110.46 | 2019 | |
| Astellas Pharma US INC | $47.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.23 | 2019 | |
| Halozyme INC | $23.93 | 2023 | |
| Amarin Pharma, INC. | $22.22 | 2019 | |
| Eisai INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Chidakel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.